文献速递神经介入MR

高级别胶质瘤治疗中术中MRI的成本效益分析

Cost-effectiveness of Intraoperative MRI for Treatment of High-Grade Gliomas.
PubMed 文献 · Radiology · 2019-03-26

本研究构建五状态微观模拟模型,比较10万例接受术中MRI与10万例未接受术中MRI的高级别胶质瘤患者,从初次切除至死亡。术中MRI增加0.18质量调整生命年(QALY),增量成本13 447美元,增量成本效益比为每QALY 76 442美元;在10万美元/QALY的支付意愿阈值下,概率敏感性分析显示术中MRI具有成本效益的概率为99.5%。

要点

  • 术中MRI使每例患者增加0.18 QALY,增量成本13 447美元,ICER为76 442美元/QALY。
  • 在10万美元/QALY支付意愿阈值下,术中MRI具有成本效益的概率为99.5%。
  • 模型基于随机对照试验数据,PFS、效用值、概率和成本优先取自随机对照试验。

核心结论

  • 术中MRI可能是一种治疗高级别胶质瘤具有成本效益的方式。

研究设计与样本

  • 构建整合五状态微观模拟模型,比较10万例接受术中MRI与10万例未接受术中MRI的高级别胶质瘤患者,从初次切除和减瘤至死亡,初始切除中位年龄55岁;PFS、效用值、概率和成本尽可能取自随机对照试验,否则使用国家数据库、登记处和非随机试验;采用确定性及概率敏感性分析,从医疗保健视角分析,支付意愿阈值为每QALY 100 000美元。

诊断标准与关键数值

  • 术中MRI vs 未用术中MRI:QALY 1.34 vs 1.16,增量获益0.18 QALY;成本176 460美元 vs 163 013美元,增量成本13 447美元;增量成本效益比76 442美元/QALY;概率敏感性分析显示在100 000美元/QALY阈值下具有成本效益的概率为99.5%。

临床应用与阅片要点

  • 作者认为术中MRI可能是治疗高级别胶质瘤具有成本效益的方式。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Intraoperative MRI has been shown to improve gross-total resection of high-grade glioma. However, to the knowledge of the authors, the cost-effectiveness of intraoperative MRI has not been established. Purpose To construct a clinical decision analysis model for assessing intraoperative MRI in the treatment of high-grade glioma. Materials and Methods An integrated five-state microsimulation model was constructed to follow patients with high-grade glioma. One-hundred-thousand patients treated with intraoperative MRI were compared with 100 000 patients who were treated without intraoperative MRI from initial resection and debulking until death (median age at initial resection, 55 years). After the operation and treatment of complications, patients existed in one of three health states: progression-free survival (PFS), progressive disease, or dead. Patients with recurrence were offered up to two repeated resections. PFS, valuation of health states (utility values), probabilities, and costs were obtained from randomized controlled trials whenever possible. Otherwise, national databases, registries, and nonrandomized trials were used. Uncertainty in model inputs was assessed by using deterministic and probabilistic sensitivity analyses. A health care perspective was used for this analysis. A willingness-to-pay threshold of $100 000 per quality-adjusted life year (QALY) gained was used to determine cost efficacy. Results Intraoperative MRI yielded an incremental benefit of 0.18 QALYs (1.34 QALYs with intraoperative MRI vs 1.16 QALYs without) at an incremental cost of $13 447 ($176 460 with intraoperative MRI vs $163 013 without) in microsimulation modeling, resulting in an incremental cost-effectiveness ratio of $76 442 per QALY. Because of parameter distributions, probabilistic sensitivity analysis demonstrated that intraoperative MRI had a 99.5% chance of cost-effectiveness at a willingness-to-pay threshold of $100 000 per QALY. Conclusion Intraoperative MRI is likely to be a cost-effective modality in the treatment of high-grade glioma. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Bettmann in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Abraham P, Sarkar R, Brandel MG, et al. Cost-effectiveness of Intraoperative MRI for Treatment of High-Grade Gliomas. Radiology. 2019. PMID: 30912721. doi:10.1148/radiol.2019182095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。